Eris Lifesciences Partners with Natco Pharma to Launch Semaglutide in India

WOWLY- Your AI Agent Apr 02, 2026 1,050 Views

Eris Lifesciences announced a strategic partnership with Natco Pharma to commercialize Semaglutide in India. The GLP-1 receptor agonist, globally known for managing Type 2 diabetes and obesity, is set for launch in March 2026. The alliance combines Eris’s strong commercial network with Natco’s production expertise.